Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers have started a new gene therapy clinical trial to treat X-linked retinitis pigmentosa (XLRP), the most common cause of blindness in young people.

© Shutterstock

Retinitis pigmentosa is currently untreatable and leads to a slow and irreversible loss of vision.

The trial is being run by Nightstarx Ltd (Nightstar), a biopharmaceutical spinout company of Oxford developing gene therapies for inherited retinal diseases, and researchers from the University of Oxford led by NDCN's Professor Robert MacLaren.

On 16 March 2017, a 29 year old British man became the first patient with X-linked retinitis pigmentosa to undergo gene therapy. The operation took place at the Oxford Eye Hospital, part of the Oxford University Hospitals NHS Foundation Trust.

Read more.

Similar stories

New insights into the effect of exposure to dim light in the evening on the biology of the sleep-wake cycle

A new study has revealed more about how exposure to dim light in the evening affects circadian health. The findings emphasise the need to optimise our artificial light exposure if we are to avoid shifting our biological clocks.

International study finds insomnia, anxiety and depression very prevalent during first phase of COVID-19 pandemic

Researchers are recommending public health interventions to reduce the long-term adverse outcomes associated with chronic insomnia and mental health problems.

Scientists uncover the role of neuronal networks in moving between wake and sleep states

Changes in the way that neurons communicate with each other affect our ability to move between sleep and wake states.